Table 3 Effect of GSH on PV VLP thermostability.

From: A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation

 

Temperature (°C) at which 50% D-Antigenicity was lost (Temperature difference between treated and non-treated samples)

VLP Prep*

No GSH

+1 mM GSH

+5 mM GSH

+10 mM GSH

IPV (type 3)

50.0 °C

   

MVA PV2 MEFSC6b

52.0 °C

55.0 °C (↑3 °C)

>55.0 °C (↑>3 °C)

>70.0 °C (↑>18 °C)

MVA PV3 SktSC8

56.0 °C

66.0 °C (↑10 °C)

67.0 °C (↑11 °C)

67.0 °C (↑11 °C)

MVA wt PV2

34.5 °C

40.5 °C (↑6 °C)

41.5 °C (↑7 °C)

42.5 °C (↑8 °C)

MVA wt PV3

35.0 °C

 

41.0 °C (↑6 °C)

 

Yeast PV1 MahSC6b

43.5 °C

48.0 °C (↑4.5 °C)

52.5 °C (↑9 °C)

51.5 °C (↑8 °C)

Yeast PV2 MEFSC6b

45.5 °C

48.0 °C (↑2.5 °C)

50.0 °C (↑4.5 °C)

50.0 °C (↑4.5 °C)

Yeast PV3 SktSC8

55.0 °C

55.5 °C (↑0.5 °C)

53.0 °C (↓2 °C)

55.0 °C (=)

  1. IPV inactivated polio vaccine (derived from virus).
  2. *Both mammalian-expressed (MVA) and yeast-expressed VLPs had naturally derived pocket factors.